BioNTech SE (BNTX) Profit After Tax (2018 - 2026)
BioNTech SE (BNTX) posted Profit After Tax of -$355.0 million for Q4 2025, down 958.16% sequentially from -$33.6 million in Q3 2025, and down 228.03% YoY from $277.3 million in Q4 2024.
Analysis
BioNTech SE (BNTX) Profit After Tax (2018 - 2026) Analysis & Trends
BioNTech SE has reported Profit After Tax for 8 years, with the latest figure at -$355.0 million in Q4 2025.
- Quarterly Profit After Tax fell 228.03% year-over-year to -$355.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.3 billion (down 76.14% YoY) and the FY2025 annual result came in at -$1.3 billion, down 80.55% from the prior year.
- Profit After Tax eased to -$355.0 million in Q4 2025 per BNTX's latest filing, from -$33.6 million in the prior quarter.
- Over five years, Profit After Tax peaked at $4.2 billion in Q1 2022 and troughed at -$869.9 million in Q2 2024.
- A 5-year average of $1.1 billion and a median of $385.0 million in 2023 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2021 and 2024: Profit After Tax soared 827987404.69% in 2021, then sank 319.57% in 2024.
- Over 5 years, Profit After Tax stood at $3.6 billion in 2021, then slumped by 35.81% to $2.3 billion in 2022, then plunged by 78.81% to $492.7 million in 2023, then sank by 43.72% to $277.3 million in 2024, then plunged by 228.03% to -$355.0 million in 2025.
- According to Business Quant data, Profit After Tax over the past three periods registered -$355.0 million, -$33.6 million, and -$437.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -16.62 Mn |
| 10 | BioNTech SE | 25.12 Bn | 11.47 Bn | 10.00 Mn | -954.07 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -954.07 Mn |
| Mar 31, 2026 | -622.72 Mn |
| Dec 31, 2025 | -355.03 Mn |
| Sep 30, 2025 | -33.55 Mn |
| Jun 30, 2025 | -437.62 Mn |
| Mar 31, 2025 | -437.37 Mn |
| Dec 31, 2024 | 277.30 Mn |
| Sep 30, 2024 | 217.56 Mn |
| Jun 30, 2024 | -869.91 Mn |
| Mar 31, 2024 | -342.31 Mn |
| Dec 31, 2023 | 492.67 Mn |
| Sep 30, 2023 | 174.83 Mn |
| Jun 30, 2023 | -207.33 Mn |
| Mar 31, 2023 | 539.03 Mn |
| Dec 31, 2022 | 2.32 Bn |
| Sep 30, 2022 | 1.80 Bn |
| Jun 30, 2022 | 1.78 Bn |
| Mar 31, 2022 | 4.15 Bn |
| Dec 31, 2021 | 3.62 Bn |
| Sep 30, 2021 | 3.79 Bn |